Article Figures & Tables
Figures
- Figure 1:
Prevalence of osteoarthritis diagnoses in electronic medical records by patient age and sex.
Tables
Characteristic No. (%)* Patients with osteoarthritis
n = 29 562†Patients without osteoarthritis
n = 207 610†Age, yr, mean ± SD 67.4 (13.4) 53.5 (15.7) Sex Male 10 807 (36.6) 76 265 (42.8) Female 18 755 (63.4) 101 783 (57.2) Residence Urban 22 094 (76.0) 133 508 (77.3) Rural 6 979 (24.0) 39 137 (22.7) No. of comorbid conditions† 0 9 549 (32.3) 101 470 (57.0) 1 11 658 (39.4) 54 393 (30.6) 2 6 086 (20.6) 17 802 (10.0) 3 1 840 (6.2) 3 766 (2.1) ≥ 4 429 (1.5) 617 (0.3) Note: SD = standard deviation. *Unless stated otherwise. †Limited to other conditions for which the Canadian Primary Care Sentinel Surveillance Network has validated algorithms (i.e., hypertension, chronic obstructive pulmonary disease, diabetes mellitus, depression, epilepsy, Parkinson disease and dementia).
Age group, yr No. (%)* Men Women Overall 30–39 14 516 (1.9) 23 839 (1.5) 38 355 (1.6) 40–49 17 508 (4.9) 24 836 (5.1) 42 344 (5.0) 50–59 20 562 (10.8) 26 812 (14.0) 47 374 (12.6) 60–69 17 208 (16.7) 20 798 (23.4) 38 006 (20.4) 70–79 10 446 (24.2) 13 316 (32.7) 23 762 (29.0) 80+ 6 832 (30.0) 10 937 (38.2) 17 769 (35.1) Overall 87 072 (12.4) 12 0538 (15.6) 207 610 (14.2) *Direct age–sex-standardized prevalence estimates according to the Canadian national age–sex distribution based on data from the 2011 census.
- Table 3: Prevalence ratios for osteoarthritis adjusted for age and sex, by location of residence, BMI and smoking status
Characteristic* PR (95% CI) p value Location (n = 201 718) Urban = ref 1.00 — Rural 0.99 (0.96–1.01) 0.3 BMI group (n = 136 765) Underweight (< 18) 1.11 (1.04–1.17) < 0.001 Normal (18–24) = ref 1.00 — Overweight (25–29)† 1.04 (1.01–1.07) 0.004 Obese (> = 30)‡ 1.14 (1.11–1.17) < 0.001 Smoking n = 85 705 Never = ref 1.00 — Past 0.98 (0.95–1.01) 0.2 Current 0.90 (0.86–0.94) < 0.001 Note: BMI = body mass index, CI = confidence interval, PR = prevalence ratio. *Location data missing for 5 892 (2.8%) patients; BMI data missing for 7 388 (25%) patients with osteoarthritis and 64 910 (36.5%) patients without osteoarthritis; smoking data missing for 15 980 (54%) patients with osteoarthritis and 105 925 (59.5%) patients without osteoarthritis. †p < 0.01. ‡p < 0.001.
- Table 4: Age- and sex-adjusted prevalence ratios for comorbidity among patients with osteoarthritis
Comorbidity PR (95% CI) p value Hypertension 1.17 (1.15–1.19) < 0.001 Diabetes 1.02 (0.99–1.05) NS Depression 1.26 (1.22–1.30) < 0.001 COPD 1.16 (1.11–1.21) < 0.001 Dementia 1.00 (0.95–1.06) NS Epilepsy 1.27 (1.13–1.43) < 0.001 Parkinsonism 1.08 (0.93–1.24) NS Note: CI = confidence interval, COPD = chronic obstructive pulmonary disease, NS = not significant, PR = prevalence ratio.
- Table 5: Prevalence of osteoarthritis by number of other conditions (i.e., multimorbidity)
No. of other conditions Osteoarthritis present, %
n = 29 562Osteoarthritis absent, %
n = 178 0480 32.3 57.0 1 39.4 30.6 2 20.6 10.0 3 6.2 2.1 4 or more 1.5 0.3 Total 100.0 100.0 Drug class Patients, no. (%) Agent Patients, no. (%) Acetaminophen (alone or in combination) 7 424 (25.1) Acetaminophen alone 4 725 (16.0) Acetaminophen in combination 2 699 (9.1) NSAIDs 16 732 (56.6) Celecoxib 5 022 (17.0) Diclofenac* 8 752 (29.6) Ibuprofen 1 210 (4.1) Meloxicam 1 963 (6.6) Naproxen 5 885 (19.9) Other NSAIDs† 3 023 (10.2) Narcotics 9 761 (33.0) Codeine 6 881 (23.3) Hydrocodone 462 (1.6) Hydromorphone 1 164 (3.9) Morphine 784 (2.7) Oxycodone 1 488 (5.0) Tramadol 2 299 (7.8) Note: NSAID = nonsteroidal anti-inflammatory drug. *There were 4 808 patients with prescriptions for diclofenac, about 45% of which were in the form of topical gel or cream. †Diflunisal, etodolac, floctafenine, flurbiprofen, indometacin, ketoprofen, ketorolac, lumiracoxib, nabumetone, piroxicam, rofecoxib, sulindac, tiaprofenic acid and valdecoxib.
In this issue
Article tools
